tumours were reported to overexpress cFLIP, and were resistant to signals through CD95 (Irmler et al, 1997) . However, cells that are resistant to CD95-mediated signalling can be sensitized by treatment with cycloheximide (CHX), actinomycin D, brefeldin A, or interferon (INF)-γ (von Reyher et al, 1998) , although the mechanism for sensitization remains unclear.
Mammalian cells respond to ionizing irradiation in a variety of ways, depending on the type and condition of the cell. In response to DNA damage, the tumour suppressor protein p53 activates two opposing cellular pathways, one resulting in cell-cycle arrest and one triggering apoptosis (reviewed in Ashkenas and Werb, 1996) . Thymocytes are highly sensitive to γ-irradiation and die rapidly by apoptosis in a p53-dependent fashion following a single dose of 1 Gy (Clarke et al, 1993; Lowe et al, 1993) . Carcinoma cells are more resistant to the effects of ionizing irradiation; in one recent study, a single large dose of γ-rays (> 12 Gy) induced measurable cell death in some, but not all carcinoma cell lines (Zhan et al, 1994) . Human carcinoma patients typically cannot be irradiated with high doses; instead, clinical irradiation is routinely fractionated into relatively small, daily doses (Lichter and Lawrence, 1995) .
We have previously reported that treatment of tumour cells with ionizing radiation induces up-regulation of surface CD95 expression, but only in cells exhibiting wild-type p53 activity (Sheard et al, 1997) . To evaluate whether ionizing irradiation might contribute to tumour cell vulnerability by increasing the response to CD95-mediated apoptotic signals, human epithelial tumour cells were treated with high-dose or fractionated low-dose γ-irradiation and examined for susceptibility to CD95-mediated apoptosis.
Fractionated γ-irradiation renders tumour cells more responsive to apoptotic signals through CD95 MATERIALS AND METHODS

Cell cultures
Human colorectal carcinoma (HCT116 and HT29), breast adenocarcinoma (MCF-7, BT549, MDA-MB231), breast ductal carcinoma (T47D), cervical carcinoma (HeLa) and osteosarcoma (SAOS-2) cells were cultured in Dulbecco's modified Eagle's medium (DMEM) . For experiments involving a single dose of radiation, cells were plated at sub-confluence in 75 cm 2 tissue culture flasks (Nalge Nunc International, Denmark) 1 day prior to irradiation, and maintained in 10% fetal calf serum (FCS). During dose-fractionated experiments, cell cultures consistently expanded to confluency, regardless of low starting concentrations; fresh medium containing 1% FCS (except where noted) was supplied every 3 days, 8 h after irradiation (to avoid conflict between transient post-irradiation p53 activity and serum-derived mitogenic signals), and 1 day before anti-CD95 treatment (to avoid conflict between CD95-induced apoptotic signals and mitogenic signals from freshly-administered serum). The status of p53 has been reported for all cell lines studied.
Radiation treatment
Cell lines were γ-irradiated from a 60 Co source (dose rate 1.30 Gy min -1 ). To assess basal levels of CD95, equivalent cell cultures were mock-treated by removing from incubators and tightening caps during the irradiation periods. For fractionated irradiation, cells were exposed daily to 2 Gy for 8 consecutive weekdays, Tuesday to Friday in the first week, Monday to Thursday in the second week.
Induction and inhibition of CD95-mediated apoptosis
Eight hours after completion of irradiation, agonist anti-CD95 IgM monoclonal Ab (clone CH11, Immunotech, Westbrook, ME, USA) was added directly to cell cultures for a final concentration of 1 µg ml -1 (in CD95-resistant cells) or 0.2 µg ml -1 (in partiallysensitive cells), and cells were incubated for 44 h (in single-dose experiments) or 20 h (in fractionated-dose experiments) in 5% carbon dioxide at 37°C prior to harvesting. Prior to addition of agonist Ab, CD95-resistant cells were pretreated with cycloheximide (10 µg ml -1 ) (SIGMA, St Louis, MO, USA) for 30 min. To inhibit CD95-mediated apoptosis, the previously described antagonistic F(ab′) 2 Ab fragments (anti-APO-1) (Dhein et al, 1995) were added at 1 µg ml -1 30 min before addition of agonist Ab in single-dose experiments, or immediately after every exchange of medium when examining potential CD95/CD95-L interactions during fractionated irradiation.
DNA content analysis
For measurement of DNA content, adherent and floating cells were washed separately, pooled together, and incubated for at least 4 h at 4°C in 400 µl DNA staining solution (50 µg ml -1 propidium iodide, 0.1% Triton X-100, 0.07% RNase, 0.1% sodium chloride). Cells were analysed by flow cytometry in their staining solution diluted to 0.8 ml with modified Hank's balanced salt solution (HBSS). A 630 nm band-pass filter was used to collect red fluorescence. In each histogram, a gate was applied to the lowest spectrum of the linear FL3 channel at the distinct border between apoptotic cells and subcellular debris. Data were acquired in linear mode instead of logarithmic mode to reduce the negative aspect associated with setting subjective gates on forward and sidescatter parameters when delineating between late apoptotic events and subcellular debris (late apoptotic cells are a source of debrisrelated noise), which was more problematic when very lowstaining FL3 signals were included into analyses using a logarithmic scale.
TdT-mediated dUTP nick end labelling (TUNEL)
TUNEL technique was performed using a kit (Boehringer Mannheim, Mannheim, Germany) according to instructions provided by the manufacturer, with several modifications. Briefly, harvested cells (adherent plus floating) were transferred to 'eppendorf' tubes and washed twice in modified HBSS containing 0.2% bovine serum albumin (BSA) and 0.1% sodium azide (NaN 3 ); to avoid excessive cell loss during the many washing steps, all washes were performed by centrifuging cells for 8 min at 300 g (in early washes), aspirating supernatants to a minimal volume using individual disposable pipettes, and adding a few drops of medium to each tube for adequate volume during subsequent vortexing. Cells were fixed in 4% paraformaldehyde for 30 min at room temperature. After two washes in phosphate-buffered saline (PBS), cells were resuspended in permeabilization solution (0.1% Triton X-100, 0.1% sodium citrate) for 5 min and washed twice (spin rate was henceforth increased to 400 G to improve cell yield). To relieve compaction of DNA by histones, cells were incubated in proteinase K (20 µg ml -1 ) at 37°C for 20 min. Following two washes, cells were incubated in the provided staining solution for 2 h at 37°C, washed twice, and analysed by flow cytometry.
Determination of surface protein expression
Cells were harvested with 0.1% trypsin, 0.25% EGTA in modified HBSS without calcium or magnesium, and maintained in modified HBSS containing 0.2% BSA and 0.1% NaN 3 . Cells were washed twice, stained with fluorescein isothiocyanate (FITC)-conjugated monoclonal anti-human CD95 (clone UB2) or FITC-IgG1 isotype control Ab (Immunotech, Westbrook, ME, USA), washed twice, and analysed by flow cytometry using an EPICS XL (Coulter, Hialeah, FL, USA). The voltage applied to the FL1 channel was selected for each treatment-group in a given cell type so that the mean fluorescence intensity (MFI) of irrelevant Ab-treated controls was similar. Indices of MFI values were calculated using the formula: MFI Index = (MFI of anti-CD95 Ab-stained cells/MFI of irrelevant Ab-stained cells). Dead cells and debris were excluded according to their increased staining with propidium iodide and low forward scatter properties. At least 10 000 viable cells were interrogated for each sample.
RESULTS
Response to signals through CD95 after a single large dose of γ-radiation
To evaluate whether ionizing radiation can sensitize tumour cells to apoptotic signalling through CD95, HCT116 colorectal carcinoma cells were treated with 16-Gy γ-rays. Eight hours later, irradiated and control cells were treated with CHX, with an agonistic cross-linking anti-CD95 Ab, or both, and then incubated another 2 days. DNA content was evaluated for each cell by staining with propidium iodide and analysing by flow cytometry. Only a low percentage of untreated HCT116 cells contained a DNA content less than observed in G1 phase of the cell-cycle (sub-G1); (we avoid the common term 'subdiploid', since many tumour cell lines in G1 phase contain an aneuploid number of chromosomes). Treatment of unirradiated control cells with agonist anti-CD95 Ab alone had no significant effect on the percentage of sub-G1 events ( Figure 1A , upper left panels), indicating that HCT116 cells are resistant to signals through CD95. Treatment with CHX alone had no reproducible effect on cell viability, but the combination of CHX with anti-CD95 Ab induced a significant increase in the percentage of sub-G1 events ( Figure  1A , left panels). This increase in cell-death was almost completely abolished by prior incubation with an antagonist (non-signalling) anti-CD95 Ab.
A small increase in the percentage of sub-G1 events was observed 2 days after γ-irradiation with 16 Gy ( Figure 1A , upper panels). As in unirradiated controls, the viability of irradiated cells was not affected by agonist anti-CD95 Ab alone, indicating that large-dose irradiation by itself does not sensitize these resistant cells to CD95 signals. A substantial increase in sub-G1 events was observed when radiation treatment was combined with CHX plus agonist anti-CD95 Ab, and this increase was larger than observed after treatment with CHX plus agonist anti-CD95 Ab in the absence of irradiation ( Figure 1A) .
Enhanced responsiveness was also observed when cells were examined for DNA strand breaks by TUNEL staining. Significant DNA breakage was observed in irradiated cells treated with CHX plus agonistic anti-CD95 Ab ( Figure 1B) , which was confirmed in a parallel DNA content analysis. TUNEL staining provided poorer resolution of microscopically confirmed CD95-induced carcinoma cell death than did DNA content analysis in these experiments. These results suggest that a large dose of γ-radiation can enhance the response of CD95-sensitized tumour cells to signals through CD95.
Cumulative up-regulation of CD95 when γ-irradiation is fractionated into daily doses
One mechanism for enhancing the apoptotic response to CD95-mediated signalling may be through up-regulation of CD95 surface expression. CD95 expression is known to be regulated, in part, by the p53 protein (Owen-Schaub et al, 1995) , and carcinoma cells exhibiting wild-type p53 activity were shown to up-regulate CD95 expression 8 h after a high dose of γ-rays (Sheard et al, 1997) . However, clinical irradiation is usually fractionated into low doses, and it remained unknown whether surface expression of CD95 is sufficiently stable to accumulate during an extended course of daily fractionated treatment. To address this question, multiple cell lines with wild-type statuses of p53 were γ-irradiated with 2 Gy on 8 consecutive weekdays and examined 1 day later for CD95 expression levels. HCT116 and MCF-7 cells constitutively express a low level of CD95 on their cell surface, and this level is unaffected by repetitive mock-irradiation ( Figure 2A , top panels). As a control, these cells were treated with a single dose of 2 Gy, resulting in moderate up-regulation of CD95, or with 16 Gy, resulting in significantly higher CD95 expression (middle panels). Fractionation of the 16 Gy dose into 8 daily doses of 2 Gy (lower panels) resulted in an approximately equal enhancement of CD95 expression as obtained with the single large dose (Table 1) . Similar results were obtained with ZR-75.1 cells (Table 1) .
Six cell lines reported to exhibit aberrant p53-activity were also examined, to determine whether fractionated irradiation might affect CD95 expression in the large subset of cancer cells that possess abnormal p53 activity. A single dose of 16 Gy induced slight upregulation in HT29 cells, but not in the other five cell lines examined ( Figure 2B ). Dose-fractionated irradiation reproducibly induced slight up-regulation in two lines (HT29 and MDA-MB231), but had no significant effect on CD95 expression in the remaining four lines. All cell lines were able to up-regulate CD95 after treatment with interferon-γ, regardless of p53 status (data not shown). Taken together, these results indicate that up-regulation of CD95 is cumulative during fractionated γ-irradiation, but abundant up-regulation is limited to those cells bearing normal wild-type p53. 
Response to signals through CD95 after fractionated γ-irradiation
To examine whether fractionated radiation treatment enhances the response of CD95-resistant carcinoma cells to CD95-mediated signals, HCT116 and MCF-7 cells were γ-irradiated with 2 Gy on 8 consecutive weekdays. Eight hours after completion of fractionated irradiation, cells were treated with CHX and/or agonist anti-CD95 Ab, incubated another 20 h, and examined for DNA content.
Incubation with agonist anti-CD95 Ab alone did not alter the percentage of sub-G1 events in either mock-irradiated or sequentially-irradiated cells, indicating that fractionated irradiation did not overcome the inherent resistance of these tumour cells to CD95-mediated signals ( Figure 3A) . Incubation with agonist anti-CD95 Ab in the presence of CHX resulted in a substantially larger increase in the percentage of sub-G1 events in sequentially-irradiated cells than in identically treated mock-irradiated cells ( Figure  3A ). Prior incubation with antagonist anti-CD95 Ab specifically 
B
inhibited induction of sub-G1 events. Thus, HCT116 and MCF-7 cells were rendered more responsive to CD95-mediated signals by fractionated irradiation, but only when supplied sensitizing pretreatment (e.g. CHX).
To extend these observations, two partially-sensitive carcinoma cell lines that do not require sensitizing pretreatment were examined. HT29 and T47D cells undergo a modest degree of apoptosis in response to treatment with agonist anti-CD95 Ab alone, but only after relatively long incubation times. Incubation with agonist Ab induced a small increase in sub-G1 events in mock-irradiated cells, but a significantly larger increase was reproducibly observed after identical treatment of sequentially-irradiated cells ( Figure  3B ). These data indicate that fractionated γ-irradiation alone is sufficient to enhance the vulnerability of partially-sensitive carcinoma cells to CD95-mediated apoptosis. Since HT29 and T47D cells express mutant p53 and exhibit little or no up-regulation of CD95 after fractionated irradiation ( Figure 2B ), the observed enhancement of responsiveness to CD95-mediated signals was independent of wild-type p53 status and CD95 up-regulation.
The T47D cells in our experiments contained subpopulations with approximately tetraploid (4N) and octaploid (8N) numbers of chromosomes ( Figure 3B , channels 400 and 800), as previously reported (Graham et al, 1989) . Following fractionated irradiation, an apparent accumulation of T47D and HCT116 cells in peaks containing 4N was observed (Figure 3 A, B) . This accumulation was due, at least in part, to irradiation-induced generation of polyploidy, since these cells accumulated near-octaploid and eventually near-16N populations after fractionated irradiation (data not shown), and should not be interpreted as indicative of G2 cellcycle arrest at these low doses.
To investigate whether autologous CD95/CD95-L signalling (Friesen et al, 1996; Fulda et al, 1997; Müller et al, 1997 ) might be involved in radiation-induced death in the model studied here, sequentially-irradiated cells were continuously incubated in the presence of antagonist anti-CD95 Ab throughout the 11 day protocol from the first dose of 2 Gy to harvest. Continuous culturing with antagonist anti-CD95 Ab did not prevent the formation of either radiation-induced sub-G1 events (Figure 3 A, B) or classical radiation-induced morphology involving cellular enlargement and vacuolation (Figure 4 A, B) , even though the same concentration of antagonist Ab inhibited the formation of both sub-G1 events and morphological changes induced by agonist anti-CD95 Ab treatment. Relatedly, continuous inhibition of CD95/CD95-L interactions did not prevent radiation-induced polyploidy in T47D ( Figure 3B ) and HCT116 (data not shown) cells. Taken together, these results indicate that autologous CD95/CD95-L signalling did not mediate the damaging effects of fractionated γ-irradiation on the four cell lines examined.
DISCUSSION
Many proteins are only transiently expressed in cells. For example, p53 expression increases 2-3 h after treatment of MCF-7 cells with ionizing radiation, but then rapidly declines (Lu and Lane, 1993) . Transiently expressed proteins responding to cellular stress would not be expected to accumulate over time during daily dose-fractionation. However, evaluation of CD95 expression during fractionated γ-irradiation of p53
wild-type cells reveals that fractionation of treatment into small daily doses results in strong up-regulation of CD95 expression levels, demonstrating that CD95 is sufficiently stable on the cell surface to allow accumulation during dose-fractionation. This supports the possibility that clinical radiotherapy of wild-type p53-expressing tumours may result in cumulative and prolonged elevation of CD95 expression, which may endure throughout the entire course (e.g. 30 fractions) of radiation therapy.
Daily fractionated γ-irradiation enhanced the response to CD95-mediated signals in four of four carcinoma cell lines. However, irradiation-induced increases in CD95 expression alone were not sufficient to sensitize CD95-resistant cells to CD95-mediated signals in the absence of CHX, and the responsiveness to CD95-mediated signals in two of the four cell lines was increased in spite of little or no detectable up-regulation of CD95, indicating that CD95 up-regulation is not a critical factor for enhancing the responsiveness to CD95-mediated signals. This latter finding is similar to a report that inhibition of protein export with brefeldin A prevents up-regulation of surface CD95 and yet sensitizes carcinoma cells to CD95-mediated signals (von Reyher et al, 1998) . The question of whether, and to what extent, increases in CD95 expression can influence the apoptotic response to CD95-mediated signals has not been specifically addressed in this work. Notably, it has been reported that sensitization to CD95-mediated signalling can be obtained in CD95-resistant MCF-7 cells by genetically engineered overexpression of CD95 in the presence of protein A or sphingomyelinase (Jäättelä et al, 1995) , leaving open the possibility that the magnitude of increased CD95 expression may influence the sensitivity of CD95-resistant cells.
The possibility that induction of tumour cell death by radiation treatment might involve autologous killing through CD95/CD95-L interactions has been suggested by the following observations: (i) ionizing radiation stimulates production of ceramide (HaimovitzFriedman et al, 1994) , (ii) γ-radiation-induced production of ceramide can induce up-regulation of CD95-L , (iii) disruption of the CD95/CD95-L signalling pathway in leukaemia cells inhibited ceramide-induced apoptosis . Furthermore, it was reported that autologous CD95/CD95-L signalling can be observed following cytotoxic treatments of some leukaemia, hepatoma and neuroblastoma cells (Friesen et al, 1996; Müller et al, 1997; and Fulda et al, 1997 respectively) . However, inhibition of CD95/CD95-L interactions provided no protection from the lethal effect of daily fractionated γ-irradiation in the carcinoma cells studied here. Similarly, it has been previously reported that γ-irradiation (12 Gy) of a CD95-resistant subclone of Jurkat lymphoid cells induced cell death as efficiently as in CD95-sensitive parental cells (Eischen et al, 1997) . The absence of autologous CD95/CD95-L signalling in the direct lethal effect of fractionated γ-irradiation on CD95-partially-sensitive cells suggests that the radiation-enhanced response to signals through CD95 might be fully exploitable using other modalites for ligating CD95. An additional sensitizing agent would be required to realize a similar benefit in CD95-resistant cells.
In summary, the present study indicates that CD95-partiallysensitive carcinoma cells, and also CD95-resistant cells which are pretreated with a sensitizing agent (e.g. CHX), become more responsive to CD95-mediated apoptotic signals after fractionated γ-irradiation. No evidence was found to suggest that autologous CD95/CD95-L signalling was active in the fractionated radiationinduced death of the four carcinoma cell lines tested. Since the CD95-independent nature of fractionated radiation-induced death was coupled with increased responsiveness to CD95-mediated signals, utilization of the heightened responsiveness of these irradiated carcinoma cells to CD95-mediated signalling probably requires an exogenous source of CD95 ligation.
